Literature DB >> 16221068

Prevention of Staphylococcus aureus infections: advances in vaccine development.

Henry R Shinefield1, Steven Black.   

Abstract

Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in a minority of carriers, particularly in hospital settings. S. aureus disease is difficult to treat, and antibiotic-resistant strains have become common. Prevention of S. aureus disease would therefore be the best way to limit the morbidity and mortality caused by this organism, but its virulence is determined by a number of different factors, making design of a widely effective vaccine difficult. Here, various S. aureus virulence factors and attempts to develop vaccines or other protective drugs based on these factors are reviewed. In particular, the results of a Phase III clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221068     DOI: 10.1586/14760584.4.5.669

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  8 in total

1.  Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.

Authors:  Isabelle Verdier; Geraldine Durand; Michele Bes; Kimberly L Taylor; Gerard Lina; François Vandenesch; Ali I Fattom; Jerome Etienne
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

2.  Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.

Authors:  Jose L Raygada; Donald P Levine
Journal:  Am Health Drug Benefits       Date:  2009-02

3.  Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection.

Authors:  Sabine Rauch; Portia Gough; Hwan Keun Kim; Olaf Schneewind; Dominique Missiakas
Journal:  Infect Immun       Date:  2014-09-02       Impact factor: 3.441

4.  Staphylococcus aureus hijacks a skin commensal to intensify its virulence: immunization targeting β-hemolysin and CAMP factor.

Authors:  Chih-Wei Lo; Yiu-Kay Lai; Yu-Tsueng Liu; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

5.  Revisiting Bacterial Interference in the Age of Methicillin-resistant Staphylococcus aureus: Insights Into Staphylococcus aureus Carriage, Pathogenicity and Potential Control.

Authors:  Paul J Planet; Dane Parker; Naomi L Ruff; Henry R Shinefield
Journal:  Pediatr Infect Dis J       Date:  2019-09       Impact factor: 2.129

Review 6.  Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Authors:  Michael S Bronze; James B Dale
Journal:  Am J Med Sci       Date:  2010-09       Impact factor: 2.378

7.  Anti-Staphylococcus aureus Single-Chain Fragment Variables Play a Protective Anti-Inflammatory Role In Vitro and In Vivo.

Authors:  Lei Zhang; Xin Ye; Yan Zhang; Fengqing Wang; Fanqing Zhang; Yan Jia; Dangjin Wu; Kalbinur Tohti; Manling Cheng; Jianguo Zhu
Journal:  Vaccines (Basel)       Date:  2021-11-09

Review 8.  Staphylococcus aureus vaccines: Deviating from the carol.

Authors:  Dominique Missiakas; Olaf Schneewind
Journal:  J Exp Med       Date:  2016-08-15       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.